



1 Fa

PATENT APPLICATION

Docket No. 13695/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: FENG et al.

Application No.: 10/574,917

Filed: April 11, 2006

Group Art Unit: 1614

Examiner: To be assigned

For: USE OF L-BUTYLPHthalide IN THE MANUFACTURE OF MEDICAMENTS
FOR PREVENTION AND TREATMENT OF CEREBRAL INFARCT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO/SB/08A, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that no fees are due, but authorization is hereby given to charge any fees due, or to credit any overpayment, in connection with the filing of this Information Disclosure Statement to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Date: February 12, 2008



King L. Wong
Registration No. Reg. No. 37,500

1500 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 220-4200
Facsimile: (202) 220-4201
CUSTOMER NUMBER 26646